To summarize, our pan-cancer analysis of SMOX and SUCLG2 demonstrated their close association with clinical characteristics, prognosis, cancer immunity, cancer cell characteristics, and drug sensitivity in various cancers. This evidence concerns the gene SUCLG2 and cancer.